While pharmaceutical giants like CSL and Mayne Pharma say they'll largely escape Trump's 100% drug tariffs, industry groups warn a separate US pricing policy poses a bigger threat.
While pharmaceutical giants like CSL and Mayne Pharma say they’ll largely escape Trump’s 100% drug tariffs, industry groups warn a separate US pricing policy poses a bigger threat.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.